COSCIENS Biopharma (CSCI) 6-K Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________ 

FORM 6-K

 _______________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of August 2017

Commission file number 0-30752

 _______________________________

AETERNA ZENTARIS INC.

_______________________________ 

315 Sigma Drive, Suite 302D

Summerville, South Carolina, USA

29486

(Address of Principal Executive Offices)

 _______________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ý    Form 40-F  o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  o No  ý

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-.

DOCUMENTS INDEX

Documents Description

99.1 Press release dated August 10, 2017: Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		AETERNA ZENTARIS INC.
Date:	August 10, 2017	By:	/s/ Michael V. Ward
			Michael V. Ward
			Chief Executive Officer